Sburlati A R, Umaña P, Prati E G, Bailey J E
Institute of Biotechnology, ETH-Zürich, CH-8093 Zürich, Switzerland.
Biotechnol Prog. 1998 Mar-Apr;14(2):189-92. doi: 10.1021/bp970118s.
Genetic engineering of oligosaccharide biosynthesis pathways in mammalian cells makes possible generation of new recombinant glycoproteins of potential importance in the biopharmaceutical industry. Most prior investigations of glycosylation engineering of secreted heterologous glycoproteins involve terminal steps of oligosaccharide biosynthesis. In particular, increasing the frequency of bisected structures within the glycoform distribution has not before been considered. A Chinese hamster ovary (CHO) cell line capable of producing bisected oligosaccharides on glycoproteins was created by overexpression of a recombinant N-acetylglucosaminyltransferase III (GnT-III). Interferon beta (IFN-beta) was chosen as a model and potential therapeutic secreted heterologous protein to demonstrate the effect of recombinant GnT-III-expression on product glycosylation. IFN-beta with bisected oligosaccharides was produced by the GnT-III-engineered CHO cells but not by the unmodified parental cell line.
对哺乳动物细胞中的寡糖生物合成途径进行基因工程改造,使得有可能产生在生物制药行业具有潜在重要性的新型重组糖蛋白。此前大多数关于分泌型异源糖蛋白糖基化工程的研究都涉及寡糖生物合成的末端步骤。特别是,增加糖型分布中双叉结构的频率此前从未被考虑过。通过过表达重组N-乙酰葡糖胺基转移酶III(GnT-III),创建了一种能够在糖蛋白上产生双叉寡糖的中国仓鼠卵巢(CHO)细胞系。选择干扰素β(IFN-β)作为模型和潜在的治疗性分泌型异源蛋白,以证明重组GnT-III表达对产物糖基化的影响。带有双叉寡糖的IFN-β由GnT-III工程改造的CHO细胞产生,而未修饰的亲本细胞系则不能产生。